Under the terms of the alliance, AHP and Elan will collaborate in the research, development and commercialization of an experimental therapy called AN-1792, which has shown in pre-clinical trials to reduce and prevent development of amyloid plaque, a substance that is thought to be associated with Alzheimer's. The alliance also includes a five-year research program for the discovery and characterization of additional products.
Members of Hale and Dorr's Life Sciences Group represented American Home Products in the establishment of this important alliance.